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Aims Residual ischaemia following acute myocardial infarction (AMI) is related to an adverse outcome, although the effect of early initiation of statin therapy is unknown.
Methods A randomized, placebo-controlled, double-blind, parallel study was performed, which compared fluvastatin 80 mg daily with placebo in patients with an AMI and total cholesterol of <6·5 mmol . l 1 . Ischaemia was measured by ambulatory electrocardiographic (AECG) monitoring over 48-h at baseline, after 6 weeks and at 12 months.
Results
Five hundred and forty patients were included (83% male, age 61 11 years); 43% had an anterior AMI and 50% were treated with fibrinolytics in the acute phase. After 12 months, the total cholesterol (TC) level was reduced by 13% and LDL-C (low-density-lipoprotein cholesterol) by 21% (from 3·5 mmol . l 1 to 2·7 mmol . l 1 ) in the fluvastatin treatment group. Both TC and LDL increased by 9% in the placebo group (P<0·001 between groups). At baseline, ischaemia on AECG was present in only 11% of patients, and absent in 77%; in the remaining 11%, recordings were technically inadequate. After 6 weeks, 32/48 (67%) , and 12 months 35/46 (76%) of the patients with ischaemia on the baseline AECG, no longer showed signs of ischaemia. Nevertheless, ischaemia at baseline was predictive for the occurrence of any major clinical event (RR=2·35; 95% CI 1·39-3·2; P<0·001). Fluvastatin treatment did not affect ischaemia on AECG, nor the occurrence of any major clinical events as compared to placebo. Post-hoc analysis in patients with the most pronounced ischaemia at baseline showed a trend for a beneficial effect of fluvastatin on major clinical events (P=0·084).
Conclusion
Residual ischaemia after AMI is observed less frequently in the present study, than in earlier studies, although it is predictive for future cardiovascular events. As a result, the present study was underpowered, and no effect of fluvastatin on AECG ischaemia, or major clinical events in the first year after AMI, could be detected. The present data do not confirm other reports which support widespread use of statin treatment early after AMI. 
Introduction
Landmark clinical trials, such as 4S, CARE and LIPID demonstrate that statins (HMG-coA reductase inhibitors) are effective in secondary prevention. However, in these studies patients were enrolled at least 3 to 6 months after an acute coronary syndrome, while the actual time to enrolment ranged from a mean of 10 months to 3 years. In these major trials the benefits of statin therapy do not become apparent within the first year of treatment [1] [2] [3] . Before treatment becomes clinically relevant, statins may exert salutary effects on the endothelium leading to amelioration of dynamic stenosis of epicardial coronary vessels as well as augmentation of flow through the microcirculation, which can result in reduction of ischaemia. One way to examine this is by 48-h ambulatory electrocardiographic (AECG) monitoring [4] . Earlier data suggest that ischaemia on AECG following acute myocardial infarction (AMI) is encountered frequently, which is probably associated with complex lesion morphology in this setting [5] . Moreover, ischaemia on AECG has a strong predictive value for adverse outcome [6] [7] [8] [9] [10] . Statin therapy can reduce ischaemia on 48-h AECG monitoring in stable coronary artery disease [11, 12] , yet the effect of these drugs on ischaemia soon after AMI has never been studied. The FLuvastatin On RIsk Diminishing after Acute myocardial infarction (FLORIDA) study is a randomized, placebo-controlled, double-blind multicentre trial. It was designed to study the effect of early administration of fluvastatin 40 mg b.i.d. on ischaemia, detected by 48-h AECG monitoring, in patients with AMI. The primary hypothesis of the present study is, that an early improvement of endothelial function by lowering cholesterol reduces the incidence of myocardial ischaemia in post-AMI patients.
Methods

Patients
All consecutive patients with an AMI were screened for inclusion in the trial if the total cholesterol value taken at admission or within 24 h after onset of symptoms was c6·5 mmol . l 1 . For the confirmation of the qualifying AMI, an elevation of the myocardial band of creatinine phosphokinase (CK-MB) and/or total CK dtwice the upper limit of normal was required. In addition, eligibility for the study also required one of the following: new or markedly increased chest pain lasting longer than 30 min, or a new pathological Q wave of d0·04 s duration, or d25% of the corresponding R wave amplitude, both in at least two contiguous leads.
Main exclusion criteria were: age <18 years, use of lipid-lowering agents within the previous 3 months, a high triglyceride level of >4·5 mmol . l 1 , known familial dyslipidaemia, severe renal failure, known hepatic disease, signs and symptoms of severe heart failure (New York Heart Association class IV), a scheduled percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) and comedication that influences the ST-segment (digoxin, quinidine or tricyclic antidepressants). Other exclusion criteria included: atrial fibrillation, WPW syndrome, complete left bundle-branch block, known pre-existent ST-segment deviations before the qualifying AMI, left ventricular hypertrophy with a pattern of strain or presence of a permanent pacemaker.
Study treatment and assessments
As soon as eligibility was confirmed, patients were invited to participate in the study. Additionally written informed consent was obtained. Subsequently, AECG monitoring was performed and treatment with either fluvastatin 40 mg b.i.d. or placebo was initiated. Treatment was commenced at least 1 day prior to hospital discharge but not later than 14 days after AMI and was continued for 1 year. It was left to the discretion of the attending cardiologist to start other standard medication, including aspirin, beta-blocking agents and/or ACE-inhibitors. If after discharge residual ischaemia on exercise test or scintigraphy was observed, the cardiologists were encouraged to take the appropriate routine measures, i.e. PCI or CABG. Clinical events were carefully registered during outpatient visits, which were planned at weeks 6, 12, 26, 40 and 52. Blood samples for lipid analysis were taken at baseline and at the 12-month follow-up visit. AECG monitoring was also performed at 6 weeks and 12 months after commencement of the use of study medication.
For the recording and analysis of ischaemia, a threechannel Marquette system was used (Marquette Systems, Milwaukee, WI, U.S.A.). In the participating centres the leads of the recorders were attached in a standardized manner according to a protocol, using modified V 1 , modified V 5 and AVF leads, as previously described [12] . Tapes were analysed in the AECG core laboratory (University Hospital Groningen) by experienced technicians.
The study was conducted in accordance with the Declaration of Helsinki as revised in 1996 in 28 participating medical centres in The Netherlands, and in all participating centres the local ethics committees had approved the protocol prior to the study.
Study end-points
Major clinical events were defined as cardiovascular death (sudden death, fatal recurrent AMI, fatal stroke or other cardiovascular death), non-cardiovascular death, recurrent AMI or recurrent ischaemia necessitating hospitalization or revascularization (PCI, CABG). An Independent Data and Safety Monitoring Committee, blinded for treatment groups, adjudicated all major clinical events.
Ischaemia, as recorded by AECG, was defined as the presence of at least one episode showing d0·1 mV horizontal or down-sloping ST-segment depression, 80 ms after the J point, lasting for d60 s and separated by at least 60 s from the next episode. Ischaemic burden was defined as the product of duration of ischaemia and the amount of ST-segment depression (mm . min) using standard criteria [12] . The primary end-point of this study was a composite end-point, consisting of the presence of either ischaemia on AECG monitoring at 12 months or the occurrence of a major clinical event during the study.
Secondary end-points included the 6-week occurrence of the composite end-point, the 6-week and 12-month occurrence of ischaemia on the ambulatory ECG (without taking clinical events into account), the 6-week and 12-month change in ischaemic burden, the time to a major clinical event and the 12-month change in lipid profile.
Statistical analyses
All randomized patients were included in the analysis of time to a major clinical event and lipid profiles. For the analysis of AECG related end-points, patients with a missing AECG at 12 months or at 6 weeks, respectively, were excluded. For the analyses of the primary composite end-point, patients with a missing 12-month AECG who had been free of intercurrent clinical events throughout the year were excluded.
Continuous data are presented as mean and standard deviation (SD). The two treatment groups were compared using one-way analysis of variance if normally distributed, or by (Mann-Whitney) Wilcoxon's two sample test if the distribution was skewed. Categorical data are presented by percentage and count of each category. Treatment comparisons were made using Fisher exact or Chi-square tests.
Time-to-event analysis was performed using log rank tests. These data are presented as Kaplan-Meier survival curves. In the analysis of ischaemia, logistic regression was used, with treatment and baseline ischaemia as independent variables. Odds ratios (OR) and 95% confidence intervals (95% CI) are given for the results of logistic regression analysis. A P-value of <0·05 was considered statistically significant. All analyses were performed using commercially available computer software (Statistical Analysis System version 6.12, SAS Institute, Cary, NC, U.S.A.).
Considering the reported incidence of ischaemia on AECG monitoring post-AMI [10] and the published reduction of ischaemia with statins in stable coronary artery disease [11, 12] , it was estimated that inclusion of 250 patients in each arm was sufficient to show difference of effects in the described population. The assumption was that the incidence of baseline ischaemia would be at least 25%, with a reduction of at least 30% in the treatment arm and no significant change in the placebo-treated arm. In addition, it was assumed that during the study, a drop-out rate of 10% would be present due to technical AECG failures.
Results
Baseline characteristics
A total of 540 patients with an AMI were included in this study. Patients were included into the study from July 1997 until May 1999, and were followed until mid 2000. The median time to initiation of study medication after the onset of symptoms was 8 days. Seven patients were not compliant with the eligibility criteria for AMI, but were classified as eligible for analysis by the Data Safety and Monitoring Committee on the basis of the presence of an acute coronary syndrome. Of these patients, 265 were randomly assigned to fluvastatin and 275 to a placebo, and their baseline characteristics are listed in Table 1 . At baseline, beta-blockers were used in 91% of the patients in each treatment group. A number of patients in the fluvastatin and placebo groups was also receiving ACE inhibitors (38% and 36%, respectively) and calcium channel blockers (17% and 15%, respectively). The AMI was anterior in 41% and 44%, and fibrinolytics were used in 52% and 48% respectively.
The median duration of treatment was 362 days (range 3-438 days) in the fluvastatin group vs 363 (range 2-418 days) in placebo-treated group. Treatment was temporarily discontinued due to an adverse event in 5·9% of patients and permanently discontinued in 12·4%, evenly distributed between both treatment arms for temporal discontinuation (fluvastatin 6·0% vs placebo 5·8%) as for permanent discontinuation (11·3% vs 13·5%).
In 11% of patients (33 fluvastatin vs 29 placebo), the baseline AECG recording could not be interpreted due 
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to technical failures (wrong lead placement, inadequate ECG signal, etc). In the remaining 478 patients, residual ischaemia at baseline was similar in the two treatment groups, i.e. 28/232 or 12%, and 32/244 or 13%, in the fluvastatin and placebo groups, respectively (Table 2) .
Lipid parameters
At baseline, there were no differences between the two groups ( Fig. 1 .
Major clinical events
Major clinical events were evenly distributed in both treatment arms (Table 2 ). In total, 62 patients in the fluvastatin group and 68 patients in the placebo group had at least one major clinical event (P=0·764). All-cause mortality was 2·6% in the fluvastatin treated patients vs 4·0% in placebo treated patients. When patients were revealed to have ischaemia on 48-h AECG at baseline, more occurrences of any major clinical event were noticed during follow-up, compared to the patients with no ischaemia at baseline (38% and 22%, respectively).
The presence of ischaemia at baseline was also predictive for composite end-points (RR=2·35, 95% CI, 1·39-3·72; p=0·0003). The time to first major clinical event analysis is depicted in the Kaplan-Meier curve in Fig. 2 . 
Ambulatory ECG monitoring
Of all patients who showed ischaemia at baseline, only 29% and 38% of AECG recordings at 6 weeks (on fluvastatin and placebo, respectively), and 27% and 21% after 12 months, respectively were again positive for ischaemia (P=ns). The new development of ischaemia at AECG monitoring in the patients without ischaemia at baseline were 5% and 2% at 6 weeks, respectively, and 3% and 8% at 12 months (P=ns). These data are depicted in Table 2 . The 6-week and 12-month ischaemic burden was lowered by 6·1% and 7·7%, respectively, on fluvastatin, and by 10·5% and 13·5%, respectively, on placebo (P=0·81 and P=0·43, respectively between treatment groups) (figures not shown).
Composite end-point (AECG changes and major events)
The composite end-point was reached in 33% of the fluvastatin patients and 36% of the placebo patients (P=0·24). Analysis of this composite end-point at 6 weeks as well as analysis on the basis of the presence of baseline ischaemia on AECG revealed no difference with regards to treatment effect.
Subanalysis
In a post-hoc analysis of a subgroup of patients with a duration of ischaemia longer than the median of 44 min (n=30), a trend was observed in favour of fluvastatin (P=0·084). None of the other clinical variables known to possibly affect ischaemia showed any association with ischaemia or clinical events.
Discussion
This study is designed to investigate the effects of fluvastatin therapy on residual myocardial ischaemia following AMI, instituted before discharge from hospital. In contrast to earlier studies performed in a population with stable coronary artery disease, in which a treatment effect was observed, the present study shows no significant effect of fluvastatin on ischaemia as detected on 48-h AECG monitoring [11, 12] . In contrast to these earlier studies, we studied patients with a recent AMI. These patients have recently experienced one or more unstable and often complex plaques as opposed to one or more stable plaques in stable coronary artery disease. In addition, it is generally accepted to view atherosclerosis as an inflammatory disease and soon after AMI this disease is clearly more active. As a result, vasomotion of the coronary artery is different in the two conditions, and statin therapy may have a differential effect.
Apart from potential differences related to stable vs unstable ischaemic syndromes, the magnitude of the effect and the baseline value of lipid values themselves may also be of importance. In both earlier studies with stable coronary artery disease [11, 12] mean baseline LDL-C (low-density-lipoprotein-cholesterol) was markedly higher (4·3 mmol . l 1 vs 3·6 mmol . l 1 in the present study). In addition, the effect of statin treatment led to a 50% reduction in LDL-C in the study by Andrews et al. [11] , and 25% in the study by Van Boven et al. [12] . In our study, baseline values were thus lower (and less abnormal) and the treatment effect was smaller, making a potential treatment effect less likely to surface. Despite the fact that a vast number of patients in this study met the National Cholesterol Education Program (NCEP) guidelines criteria for LDL-C, this study cannot confirm reduction of ischaemia on AECG. Another consideration which has to be taken into account is the selection of the statin. Numerous studies with a diversity of statins have demonstrated that there appears to be no clinically relevant difference between drugs with respect to normalization of endothelial function, reduction of ischaemia or pleiotropic effects [13] , although a difference in potency cannot be excluded.
Ischaemia on AECG may not be the optimal surrogate marker to test the effect of statin therapy early after AMI. The current pathophysiologic model suggests that statin treatment reduces ischaemia through normalization of endothelial function. In addition, recent data indicate that statins among many other things modulate inflammation of the vessel wall and enhance neovascularization [14] [15] [16] . These beneficial effects are of particular importance for the patient with a recent AMI. Furthermore, 48-h findings on AECG may reflect endothelial function and it can be used as a surrogate marker for upcoming cardiovascular events. A confirmation of this model in this study is the finding that ischaemia at baseline after an AMI is a powerful predictor for intercurrent events. This 
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is in agreement with existing literature [6] [7] [8] [9] [10] . Another confirmation found in this study, is a trend towards less ischaemia with fluvastatin in a subgroup of patients with duration of ischaemia longer than the median of 44 min. However, this is a finding in a post-hoc analysis and is therefore speculative. Nevertheless, the described pathophysiological model still needs validation with the same or comparable surrogate markers for ischaemia in a similarly designed study in a much larger population. The observed occurrence of ischaemia after AMI in previous studies was about 25%. This study shows, however, that in current clinical practice this figure is no longer realistic as we found this in only 11% of patients. This makes the present study underpowered for investigating potential favourable effects of statins on ischaemia on a 48-h AECG. Furthermore, a significant reduction in ischaemia after 6 weeks of about 30% is noted in the placebo as well as in the fluvastatin treated group. This can probably be attributed to prescription of other drugs (in particular beta-blockers), intensive use of invasive revascularization, and spontaneous plaque stabilization [17] . A major threshold for replication of this study may be the fact that it is nowadays considered unethical to withhold cholesterol lowering therapy for 1 year to patients after AMI.
In spite of this, from a practical point of view, it is still convenient to start statin treatment before discharge following AMI, as physicians often fail to implement this therapy in the outpatient setting, as shown by EUROASPIRE data [18] . Early statin treatment is safe, as confirmed by this and other studies, and results in better patient compliance [19] . Many data, for an important part post-hoc analyses, derived from large-scale acute coronary syndrome trials, have suggested that these drug may be beneficial in this setting [20, 21] . In the only randomized, controlled study so far (the MIRACL trial), early (high-dose) statin treatment, especially after an acute coronary syndrome, was found to reduce re-hospitalization due to recurrent ischaemia [22] . However, the current evidence-based point of view is, that there is still no urgency for instituting statin treatment immediate after AMI. Therefore, other ongoing large studies will have to confirm whether early statin treatment is beneficial.
